Axel Baumgarten, MD

Zentrum für Infektiologie Berlin Prenzlauer Berg, Germany

Disclosure(s): Abbvie: Board Member; Astra Zeneca: Board Member; Gilead: Advisor/Consultant, Board Member, Honoraria; GSK/ViiV Healthcare: Board Member; Janssen: Board Member; MSD: Board Member; Pfizer: Board Member

Poster(s):

• (P-357) The Global REGAL cohort: A REtrospective real-world study of the effectiveness and tolerability of the antiretroviral treatment reGimens DTG/3TC compAred to BIC/FTC/TAF in older persons Living with HIV
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET